DUSP6-Deficient Microbiota for Obesity Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively address obesity through modulation of the gut microbiota, and the role of dual-specificity phosphatase 6 (DUSP6) in obesity development and resistance remains unclear.
Innovation Solution
Gut microbiota collected from DUSP6-deficient mammals is used to alter the relative abundance in subjects, reducing body weight, fat mass, and increasing oxygen consumption and energy expenditure, thereby treating or preventing obesity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional obesity treatment methods are used, then some weight reduction may be achieved, but they fail to effectively address obesity through gut microbiota modulation and have limited long-term efficacy
Solution Approach 1:
The invention changes the composition parameters of gut microbiota by introducing specific bacterial strains (Bacteroides fragilis, Bifidobacterium animalis, Lactobacillus acidophilus, Bifidobacterium longum) in defined ratios to achieve anti-obesity effects. This parameter change in microbiota composition resolves the contradiction by providing a reliable treatment mechanism that conventional methods lack.
Solution Approach 2:
The invention creates a composite microbiota composition combining multiple bacterial species and strains in specific proportions. This composite approach enhances treatment reliability by leveraging synergistic effects of different bacteria, while also improving adaptability to modulate gut microbiota in ways single-strain treatments cannot achieve.
2Weight of moving object
If the microbiota composition is significantly altered to achieve anti-obesity effects, then body weight and fat mass are reduced, but the complexity of identifying effective microbial combinations increases
Solution Approach 1:
The invention segments the complex microbiota modulation task into manageable components by selecting specific bacterial species and strains with known anti-obesity properties. Each strain is assigned a defined ratio (e.g., Bacteroides fragilis at 30-70%, Bifidobacterium animalis at 10-40%), breaking down the complexity into structured, implementable proportions that achieve weight reduction without overwhelming complexity.
Solution Approach 2:
The invention establishes specific parameter ranges for each bacterial component (concentration ratios, colony-forming units) to achieve anti-obesity effects. By defining these parameters upfront, the invention reduces the complexity of identifying effective combinations while maintaining the ability to significantly alter microbiota composition for weight loss.
3Power
If DUSP6-deficient mammal microbiota is used to treat obesity, then effective weight reduction and increased energy expenditure are achieved, but the mechanism by which DUSP6 deficiency mediates these effects remains unclear
Solution Approach 1:
The invention uses the gut microbiota composition from DUSP6-deficient mammals as an intermediary to transfer the anti-obesity effects to recipients. By isolating and administering the microbiota itself rather than attempting to directly manipulate DUSP6, the invention achieves increased energy expenditure and weight reduction while bypassing the need to fully understand the DUSP6 molecular mechanism.
Solution Approach 2:
The invention creates a copy of the beneficial microbiota phenotype by transferring gut bacteria from DUSP6-deficient mammals to recipients. This copying approach replicates the anti-obesity effects (reduced body weight, increased energy expenditure) without requiring elucidation of the original DUSP6 mechanism, effectively losing the mechanistic information while preserving the functional outcome.
Data Source
AI summary
The present invention relates to microbiota compositions and their preparation methods and uses. Particularly, the present invention provides microbiota compositions collected from a dual-specificity phosphatase 6 (dusp6) deficient mammal, which is effective in altering a relative abundance of gut microbiota and also useful in reducing body weight, fat mass, and/or size of adipocytes and increasing oxygen consumption and/or energy expenditure and thus can be used to treat or prevent obesity or its associated disorders or conditions in a subject in need.